Scientists at St. Jude Children’s Research Hospital collaborated to identify and improve a chemical compound that acts as a molecular “super-glue” with broad activity across cancers.
Using CRISPR/Cas9, scientists at St. Jude Children’s Research Hospital identified RBM5 as a vital component of leukemia cell fitness, making it a promising target for drug development.
Scientists at St. Jude Children’s Research Hospital found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors.
Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.
Scientists at St. Jude Children’s Research Hospital collaborated with a global group to create a more inclusive and standardized criterion for acute pediatric critical illness, with implications for improving care.
Scientists at St. Jude Children’s Research Hospital created analogs of the antibiotic spectinomycin that are significantly more effective against these highly resistant bacteria.
Discover the first images of cytonemes during mammalian neural development, serving as express routes to establish morphogen gradients and tissue patterning.
Scientists at St. Jude Children’s Research Hospital reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands.
Scientists at St. Jude Children’s Research Hospital used cryo-electron microscopy to characterize the interaction of two proteins implicated in Parkinson’s disease.
Scientists at St. Jude Children’s Research Hospital identified genetic and epigenetic mechanisms driving predisposition to this childhood kidney cancer, impacting care and treatment.
Childhood cancer survivors have a higher prevalence of prediabetes and diabetes, which increases their risk of serious disease but also offers opportunities for prevention.
St. Jude researchers will participate in multiple oral and poster presentations and education sessions as well as moderate panels during the ASH conference.
Ranked among the top healthcare leaders and innovators across the country
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
Scientists at St. Jude Children’s Research Hospital identified target genes bound and regulated by HOXA9, a protein overexpressed in high-risk leukemia, extending understanding and opening new possibilities for treatment.
Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for relapsed and recurrent pediatric leukemia and lymphomas, but not brain and solid tumors.
Scientists at St. Jude Children’s Research Hospital mapped the difference in chromatin accessibility and regulation in different pediatric acute lymphoblastic leukemia subtypes.
Scientists at St. Jude Children’s Research Hospital showed that a fusion oncoprotein can drive molecularly indistinguishable rhabdomyosarcomas arising from both muscle and blood vessel cells.
St. Jude scientists mapped the gene regulatory networks responsible for progressive differentiation states of tumor-infiltrating T cells, using a technology known as single-cell CRISPR screening to knock out or genetically perturb multiple genes potentially involved.
He has also become co-leader of the Neurobiology and Brain Tumor Program within the St. Jude Comprehensive Cancer Center. These combined units comprise one of the largest clinical brain tumor programs in North America.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right